CAMP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 8.55%, SMA50 -11.15%, SMA200 42.57%). The stock’s 14-day RSI is 51.07 (neutral), while the ATR of 0.56 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.54% below its high and over 244.06% above its low. Average 10-day trading volume of 140.67 thousand shares is below the 3-month average of 193.39 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of 57.49% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.30. Next year's EPS is expected at $871.44. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $6.50. The high target offers 247.83% upside. The low target suggests 88.41% downside. The mean target is $8.42. This offers 144.06% upside. CAMP4 Therapeutics Corporation earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 52.38%. The prior quarter beat by 180.65%. Over the last six quarters, Apple has recorded several small beats. These include 210.99% in March 27, 2025.

CAMP4 Therapeutics Corporation has 51.93 million shares outstanding. The public float is 27.47 million shares, elevated short interest at 4.10% of float. This equals 1.44 million shares. The short ratio is 4.05 days. Institutional investors hold 100.31% of the float. Insiders own 13.07%. Cummins Wes holds 3.42 million shares, 5AM Partners VI, LLC has 2.94 million shares and B. Riley Asset Management, LLC has 2.23 million shares.

CAMP4 Therapeutics Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.71. This means the shares are trading below this model’s fair value.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) closed at $3.45 USD, losing -$0.02 (-0.58%) from the previous close of $3.47. The stock is currently mid-range between its 52-week high and low $1.32 and $7.75. With a market capitalization of about $73.28 million, CAMP4 Therapeutics Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.10). Key stats such as the average daily volume over the past year has been around 190.36 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, CAMP4 Therapeutics Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua Mandel-Brehm, the company employs approximately 48 people and listed since October 11, 2024. CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A.

CAMP4 Therapeutics Corporation trades at a P/E ratio of -1.57, slightly below the S&P 500 average, with a price-to-sales ratio of 19.25 and a price-to-book ratio of 6.68 trading at moderately above to book value. The P/FCF stands at -2.88, also below market averages.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) shares are down -27.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CAMP4 Therapeutics Corporation trading at a premium to the broader market with a P/E of -1.57. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.67, suggesting 180.29% upside. Our AI forecast model points to short-term weakness (-20.58% over two weeks), a medium-term rise (36.81% over three months), and a longer-term gain (506.09% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CAMP4 Therapeutics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.58%, with price expected at $2.74 by August 14, 2026, within a range of $2.46 to $3.04 3-Month Outlook: Projected rise of 36.81%, reaching $4.72 by October 28, 2026, with a range of $4.16 to $5.09. 1-Year Outlook: Projected gain of 506.09%, with price at $20.91 by July 30, 2027, within a range of $6.37 to $24.61.